Essential Thrombocythemia vs Pre-PMF: What's the Difference?

If your pathology report mentions pre-fibrotic myelofibrosis (pre-PMF) when you were expecting a diagnosis of essential thrombocythemia (ET), it is normal to feel confused and anxious. It is common for these two conditions to be confused because there is substantial overlap on standard blood tests—both typically cause a high platelet count (thrombocytosis) ^[1][2]. They also share the same driver genetic mutations, such as JAK2, CALR, or MPL, though at different frequencies ^[1]. Having one of these mutations supports the diagnosis but cannot distinguish between ET and pre-PMF, and lacking them does not rule either condition out.

Pre-PMF is a distinct prefibrotic form of primary myelofibrosis ^[3]. While it shares many surface-level similarities with ET, differentiating between the two is critical because pre-PMF carries a higher risk of progression and may warrant closer, individualized monitoring ^[4][5].

The Bone Marrow Biopsy: The Core of the Diagnosis

Because blood work and genetic testing cannot definitively tell ET and pre-PMF apart, hematologists rely heavily on a bone marrow biopsy ^[1][6]. A specialized pathologist examines the tissue under a microscope to look for specific physical characteristics (histopathology). A diagnosis requires integrating these marrow findings with your clinical history, blood tests, and the exclusion of other diseases ^[7].

Megakaryocyte Appearance and Clustering
Megakaryocytes are the large bone marrow cells that produce platelets. Their appearance is one of the most important factors in telling these two diseases apart:

• In ET: Megakaryocytes are generally enlarged and mature, with hyperlobulated (highly folded) nuclei. They tend to be spread out or gathered in loose, small clusters ^[6][8].
• In pre-PMF: Megakaryocytes look abnormal (atypical). They may have irregularly shaped, “cloud-like” nuclei (hypolobulated) or appear as naked nuclei without the surrounding cell body ^[8][9]. They also tend to clump together in dense, tight clusters ^[6]. No single feature is diagnostic; they must be interpreted as an overall pattern.

Overall Cellularity and Other Blood Cells
The pathologist will also look at the overall crowding of the bone marrow (cellularity) and the balance of other cell types:

• In ET: The bone marrow cellularity is often normal or only slightly increased for the patient’s age. The production of white and red blood cells is generally normal ^[6][10].
• In pre-PMF: The marrow is typically hypercellular (overcrowded). There is an overgrowth of white blood cell precursors (granulopoiesis) and often a relative decrease in red blood cell precursors (erythropoiesis) ^[6][8].

Reticulin Fibrosis Grading
Your report may mention a “reticulin fibrosis grade,” which measures the amount of scarring in the marrow on a scale of MF-0 to MF-3. It is a common misconception that fibrosis grading alone can separate ET from pre-PMF. Both ET and pre-PMF typically show little to no scarring (grade MF-0 or MF-1) ^[2][11]. Overt (advanced) myelofibrosis criteria typically include grades of MF-2 or MF-3, but these grades must be interpreted alongside your clinical history and other marrow features ^[12]. Therefore, a grade of MF-0 or MF-1 does not automatically mean you have ET ^[2].

Clinical Clues Beyond the Bone Marrow

Under modern diagnostic guidelines (like the WHO or ICC classifications), a diagnosis of pre-PMF requires meeting “major criteria” (the specific bone marrow pattern, genetic markers, and ruling out other diseases) plus at least one “minor criterion” ^[13][7]. These minor criteria are clinical signs more common in pre-PMF:

• Anemia (measured by low hemoglobin or hematocrit, not just a low red blood cell count)
• Leukocytosis (an elevated white blood cell count)
• An enlarged spleen (splenomegaly)
• Elevated levels of lactate dehydrogenase (LDH), an enzyme found in the blood

Having one of these signs does not confirm pre-PMF on its own, but it supports the diagnosis when the bone marrow features are present ^[7].

Quick Comparison Table

Why Differentiating ET from Pre-PMF Matters

Getting an accurate diagnosis is the first step in ensuring you receive the appropriate monitoring and care for your specific condition.

• Risk of Progression: Pre-PMF has a higher chance of progressing to overt myelofibrosis (advanced scarring of the bone marrow). Population estimates suggest the 10-year risk of progression for pre-PMF is roughly 10% to 12% (10 to 12 out of 100 people), compared to less than 1% for ET ^[4][14]. Progression is not inevitable, but this difference means the distinction is important for your long-term care plan.
• Long-Term Monitoring: Because of the differences in progression risk, patients with pre-PMF may warrant more vigilant, individualized monitoring. Your care team will track changes in your spleen size, blood counts, and LDH levels ^[15][16].
• Treatment Approach: Treatment for both conditions is individualized based on your age, prior history, cardiovascular risks, and symptoms. While both diseases carry risks for blood clots (thrombosis) and sometimes bleeding, medication (like daily aspirin or platelet-lowering drugs) is not automatic ^[17]. Never start or stop aspirin without consulting your doctor. Seek urgent medical attention if you experience signs of a blood clot or serious bleeding, such as sudden weakness, chest pain, shortness of breath, or uncontrolled bleeding ^[17].

If your pathology report is ambiguous, a second review by a hematopathologist who specializes in myeloproliferative neoplasms (MPNs) is highly recommended ^[6][18].